Research and Markets: Teva is The Clear Market Leader since Its 2006 Purchase of IVAX States New Report Opportunities and Challenges for Generic Drugs in the UK 2007.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c61363) has announced the addition of Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. report Opportunities and Challenges for Generic Drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. in the UK 2007 to their offering. The PS2.4 billion UK generics market is one of the worlds largest in terms of both size and generic penetration. In 2005 over 59% of prescriptions were dispensed as generics, accounting for 26% of the market value. But fierce competition and price pressure are turning up the heat. How will the market continue to grow? Key areas addressed: -5-Year market forecast to 2012 for value -The generics market in context of the whole pharmaceutical industry -Pricing issues and reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. -Political, legal and economic assessment -Insightful review of 18 major domestic and foreign players in the market -Detailed listing of 18 leading products including prescription data, price comparisons and marketing authorisations Focus on developing generic markets for statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein and proton pump inhibitors Proton Pump Inhibitors Definition The proton pump inhibitors are a group of drugs that reduce the secretion of gastric (stomach) acid. They act by binding with the enzyme H+, K(+)-ATPase, hydrogen/potassium adenosine triphosphatase The UK generics market has proved a difficult operating environment In computing, an operating environment is the environment in which users run programs, whether in a command line interface, such as in MS-DOS or the Unix shell, or in a graphical user interface, such as in the Macintosh operating system. in recent years. Many established suppliers have experienced declining sales and profitability, due to a number of factors. On the one hand, the market is relatively easy to enter, leading to rapid and fierce price competition for major drugs. On the other, the UK government keeps a close watch on generic drug pricing, and has proved willing to reduce prices for a number of products in recent years. As in the wider global market, there are signs of ongoing industry consolidation. Teva and IVAX IVAX Industrial Vax (Dec Computer) both have a strong presence in the UK, making Teva the clear market leader since its 2006 purchase of IVAX. One new development is the growing arrival of US companies in the market with control of Pliva going to Barr Laboratories in 2006, and Generics (UK) set to become part of Mylan in 2007. There are no major UK-owned generic manufacturers. But who are the leading players and what are their strengths? What barriers to market entry exist? What marketing authorisations have recently been issued, and to whom? What will be the operating and regulatory environment for companies? The answers to these and many other questions can be found in this 160-page management report Opportunities and Challenges for Generic Drugs in the UK. Summary ISSUES AFFECTING THE UK GENERIC MARKET When is a generic prescription not a generic prescription? Despite great emphasis being placed on generic prescribing, a significant number of generic prescriptions are not dispensed as such. For example, in England, generics accounted for 80.1% of written prescriptions and 59.3% of prescriptions dispensed in 2005. This means around 415 million prescriptions were dispensed as generics and around 145.8 million generically-written prescriptions were dispensed as brands. There are several reasons for this; limited generic availability, availability of a cheaper parallel import brand, or on a few occasions the brand was in fact cheaper than the generic. Price fixing price fixing n. a criminal violation of federal anti-trust statutes, in which several competing businesses reach a secret agreement (conspiracy) to set prices for their products to prevent real competition and keep the public from benefiting from price competition. allegations rumble on The government, ever watchful of the rising drugs bill has taken action against a number of companies who were accused of price-fixing in the generics sector, although there appears to be no swift conclusion. In 2005, two companies Ranbaxy and Generics (UK) did deals with the Department of Health with regard to its civil action. Neither company has admitted any wrongdoing wrong·do·er n. One who does wrong, especially morally or ethically. wrong  do , but both have pledged to co-operate with
the ongoing investigations. Despite this co-operation all the companies
identified continue to be part of a criminal case brought by the Serious
Fraud Office.
Paediatric Adj. 1. paediatric - of or relating to the medical care of children; "pediatric dentist" pediatric SPC/patent extension In 2005, the European Parliament European Parliament, a branch of the governing body of the European Union (EU). It convenes on a monthly basis in Strasbourg, France; most meetings of the separate parliamentary committees are held in Brussels, Belgium, and its Secretariat is located in Luxembourg. voted in favour of the Regulation on Paediatric Medicines, which among other things grants an additional six months SPC/patent extension for drugs with additional indications for use in children. This was adopted in 2006 and came into force in January 2007. Outlook for future growth While the UK generic market is large by international standards, growth is unlikely to outpace out·pace tr.v. out·paced, out·pac·ing, out·pac·es To surpass or outdo (another), as in speed, growth, or performance. outpace Verb [-pacing, the market as a whole over the next few years. Strong competition among manufacturers exerts a strong downward pressure on prices, as does the continuing government monitoring of the UK generic industry in the wake of its various price-fixing lawsuits. In addition, the government has proved willing to step in to correct reimbursement prices, where these significantly exceed the market. The April 2005 Drug Tariff The Drug Tariff is a monthly UK publication used as a reference for the payment and repayment of NHS prescription costs in the UK by pharmacists or doctors dispensing in primary care. had the effect of reducing generic prices, and action has also been taken with regard to the price of specific drugs. Growth in the market, therefore, is likely to be driven by new products becoming available as generics, and steadily rising consumption. Generics are well accepted by consumers and widely used by doctors. The report answers key questions such as: - What is the estimated value of the UK generic market now and in 2012? - What is the current pricing and reimbursement situation for generic drugs and how might it change? - The market is set to grow over the next 5 years - what will be the drivers? - Which companies have marketing authorisation for amlodipine and how does the generic compare to the brand? - Major companies in the UK generics industry are merging - will consolidation mean greater price competition? Content Outline: Foreword Introduction Background to the Market Geography Political Overview Economic Overview Demographics Demographic indicators The UK Healthcare System Organisation Primary Care Trusts The UK Generics Market 2005 generics reimbursement scheme Generic price reductions for four major drugs DOH Holds consultations regarding branded generics in the PPRS PPRS Pharmaceutical Price Regulation Scheme (UK) PPRS Petroleum Production Reporting System PPRS Personality Profile Reporting System PPRS Promotions & Placements Referral System Regulation of Pharmaceuticals Generic regulation Intellectual Property Supplementary Protection Certificates In European Union member countries, a supplementary protection certificate (SPC) is a sui generis, patent-like, intellectual property right. This type of right is available for medicinal products, such as drugs, and plant protection products, such as insecticides, and Prescription Medicines Market England Scotland Wales Wales, Welsh Cymru, western peninsula and political division (principality) of Great Britain (1991 pop. 2,798,200), 8,016 sq mi (20,761 sq km), west of England; politically united with England since 1536. The capital is Cardiff. Outlook for Future Growth Investigations into price fixing Overview of the Domestic Industry Leading Players in the Market Marketing Authorisations in 2006 Trading Companies Wholesaling AAH aah interj. Used to express pleasure, satisfaction, surprise, or great joy. intr.v. aahed, aah·ing, aahs To exclaim in pleasure, satisfaction, surprise, or great joy: Pharmaceuticals Ltd Alliance Boots Alliance Boots Limited is a British based pharmaceuticals company, operating as a high street retailer, pharmacist and pharmaceuticals wholesaler. Alliance Boots is the dominant pharmacy chain in Britain with a 17% market share[1]. (formerly Alliance Unichem Alliance UniChem Plc ) Exclusive Distribution Deal with Pfizer Retailing Major Pharmacy Chains Appendix 1: Analysis of Leading Patent-Expired Drugs Appendix 2: Rising Use of Generics in the UK Statins Market Appendix 3: Generics in the UK PPI Market Appendix 4: Sources Appendix 5: DIRECTORY Companies Mentioned: -Actavis UK Ltd -Arrow Generics Ltd -Bristol Laboratories -Crescent Pharma -Dr Reddy's Laboratories (UK) Ltd -Generics (UK) Ltd -Genus Pharmaceuticals -Goldshield Pharmaceuticals Ltd -Focus Pharmaceuticals -Kent Pharmaceuticals -Perrigo UK Ltd -Pliva Pharma Ltd -Ranbaxy (UK) Ltd -ratiopharm UK -Rosemont Pharmaceuticals -Sandoz -Teva UK -Winthrop Pharmaceuticals -Wockhardt UK Ltd Amisulpride -Ramipril -Glimepiride -Ondansetron -Sumatriptan -Amlodipine -Citalopram -Fluconazole -Gabapentin -Lamotrigine -Meloxicam -Sertraline -Tamsulosin -Terbinafine For more information visit http://www.researchandmarkets.com/reports/c61363 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion